

## Datasheet: BUF04B

Description:	ERYTHROLYSE RED BLOOD CELL LYSING BUFFER (10x)
Name:	RED CELL LYSING BUFFER
Format:	Reagent
Product Type:	Accessory Reagent
Quantity:	100 TEST/20ml

## **Product Details**

Applications	This product has been reported to work in the following applications. This information is							
	derived from testing within our laboratories, peer-reviewed publications or personal							
	communications from the originators. Please refer to references indicated for further							
	information For general protocol recommendations, please visit www.bio-							
	rad antibadiaa aam/arataaala							
	Voc No Not Determined Suggested Dilution							
	Elow Cytometry	163	NU	Not Determined	Suggested Dilution			
	Where this product has p	at been to	atad for u	in a particular tach	nique this deep not			
	necessarily exclude its use in such procedures. Suggested working dilutions are given as							
	a guide only. It is recommended that the user titrates the product for use in their own							
	system using appropriate	negative	/positive c	ontrols.				
Instructions For Use	Bio-Rad ERYTHROLYSE is supplied as a 10X concentration solution which must be							
	diluted 1/10 with distilled	diluted 1/10 with distilled water before use.						
	Bio-Rad ERYTHROLYSE is designed for use in whole blood immunofluores procedures and is suitable for use with human, rat and mouse blood.							
	Following staining according to standard procedures (worksheets available on request),							
	2ml of diluted ERYTHRO	LYSE is a	added to 1	00ul of whole blood, n	nixed well and			
	incubated for 10 minutes at room temperature. The tubes should then be centrifuged							
	(400g 5 minutes) the supernatant decanted and cells washed once in 2ml PRS/1% RSA							
	hefore analysis by flow cytometry							
		tometry.						
References	1. Clausen, B.H. <i>et al.</i> (20	008) Inter	leukin-1be	eta and tumor necrosis	factor-alpha are			
	expressed by different subsets of microglia and macrophages after ischemic stroke in							
	mice. J. Neuroinflammation, 5:46.							
	2. Hussein, O.A. <i>et al.</i> (20	)10) Neut	rophil CD	64 Expression in Inflar	nmatory Autoimmune			
	Diseases: Its Value in Dis	tinauishir	na Infectio	n from Disease Flare	Immunol Invest 39			
	699-712	galoim						
	2 Poort D L at al (2016	) Implicat	ions of a r	oro ovorcico alkalacio i	modiated attenuation of			
	J. $reall, D.J. et al. (2010)$		iulis ul a p					
	nor 12 on its response to		quent bou	t of exercise. Amino A	cius. 48 (2): 499-504.			

4. Zarkesh-Esfahani, H. *et al.* (2001) High-dose leptin activates human leukocytes via receptor expression on monocytes. <u>J Immunol. 167 (8): 4593-9.</u>

5. Zhang, Z. *et al.* (2008) FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. <u>Exp Neurol. 210</u> (2): 681-90.

6. Zhang Z *et al.* (2012) Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats. <u>Neuroscience. 221: 140-50.</u>

7. Zhang, Z.Y. & Schluesener, H.J. (2012) HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis. Prostate. 72 (1): 90-9.
8. Li, M. *et al.* (2012) Astragaloside IV protects against focal cerebral ischemia/reperfusion injury correlating to suppression of neutrophils adhesion-related molecules. Neurochem Int. 60 (5): 458-65.

9. Villaescusa, A. *et al.* (2012) Immunophenotypic evaluation of working Labrador Retrievers and German Shepherd dogs living in the same environment. <u>Vet J. 193 (2):</u> <u>602-5.</u>

10. Elgstrouml;m E *et al.* (2015) Role of CD8-positive cells in radioimmunotherapy utilizing (177)Lu-mAbs in an immunocompetent rat colon carcinoma model. <u>EJNMMI Res. 5: 3.</u>

11. García-Sancho M *et al.* (2014) Comparative study of peripheral blood leukocytes in healthy dogs and in dogs with cancer and inflammatory diseases. <u>J Vet Diagn Invest. 26</u> (2): 282-5.

12. Karayannopoulou, M. *et al.* (2017) Evaluation of blood T-lymphocyte subpopulations involved in host cellular immunity in dogs with mammary cancer. <u>Vet Immunol</u> Immunopathol. 186: 45-50.

13. Dwivedi, S. *et al.* (2010) Rac1-mediated signaling plays a central role in secretiondependent platelet aggregation in human blood stimulated by atherosclerotic plaque. J <u>Transl Med. 8: 128.</u>

14. Grad, E. *et al.* (2019) Monocyte Modulation by Liposomal Alendronate Improves Cardiac Healing in a Rat Model of Myocardial Infarction <u>Regenerative Engineering and</u> <u>Translational Medicine. 5 (3): 280-9.</u>

15. Moreno-Vicente, J. *et al.* (2022) Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments. J Immunother Cancer. 10(1):e003735.

16. Karayannopoulou, M. *et al.* (2022) Effect of anaesthesia on cell-mediated immunity in dogs undergoing mastectomy for mammary cancer <u>Vet Anaesthes Analg. Jan 31 [Epub ahead of print].</u>

17. Hussain, K. *et al.* (2022) HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy. <u>J Exp Clin Cancer Res. 41</u> (<u>1</u>): <u>131.</u>

18. Elsayed, M.S.A.E. *et al.* (2022) Real-time PCR using atpE, conventional PCR targeting different regions of difference, and flow cytometry for confirmation of

*Mycobacterium bovis* in buffaloes and cattle from the Delta area of Egypt. <u>BMC Microbiol.</u> <u>22 (1): 154.</u>

19. Brynedal, B. *et al.* (2023) Molecular signature of methotrexate response among rheumatoid arthritis patients. <u>Front Med (Lausanne). 10: 1146353.</u>

Reus, P. *et al.* (2023) Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system. <u>J Control Release. 364: 654-71.</u>
 Agbaria, M. *et al.* (2023) Nanoparticles of VAV1 siRNA combined with LL37 peptide for

		the treatment of	of panci	reatic cancer. <u>J Control I</u>	Release. 355	<u>5: 312-26.</u>			
		22. Ptacin, J.L.	et al. (	2024) A CD25-biased ir	iterleukin-2 f	or autoimmune therapy			
		engineered via	a sem	i-synthetic organism. <u>Co</u>	mmun Med	(Lond). 4 (1): 58.			
		23. Merkulov, E.D. et al. (2025) Monocyte and Macrophage in Follicular Liquid: Predictive							
		Markers of Em Ed). 30 (1): 260	bryo Q <u>660.</u>	uality in Women with Ob	esity and Inf	ertility. <u>Front Biosci (Landmark</u>			
Storage		This product is	shippe	d at ambient temperatu	e.				
		The 10X concentrated ERYTHROLYSE should be stored at room temperature and is							
		stable for 1 yea	ar. Do r	not use if any discoloura	tion or precip	pitation occurs in the			
		ERYTHROLYS	E solut	ion. The information reg	arding the p	roducts is believed to be			
		accurate, but th	ne infor	mation and products ha	ve no warrar	nty or guarantee other than			
		those specified	l, since	the ultimate conditions	of use and th	ne variability of the materials are			
		beyond our cor	ntrol. M	e cannot be responsible	e for and we	do not intend these products or			
		the accompany	/ing info	ormation to be used for	patent infring	ement or other such violations.			
Guarant	ee	12 months fron	n date (	of despatch					
Health And Safety		Material Safety Datasheet documentation #10212 available at:							
Informat	ion	https://www.bio-rad-antibodies.com/SDS/BUF04B							
		10212							
Regulate	ory	For research purposes only							
North & South	Tel: +1 800 265	57376 Wor	ldwide	Tel: +44 (0)1865 852 700	Europe	Tel: +49 (0) 89 8090 95 21			
America Fax: +1 919 87 Email: antibody		४ ३/२। y_sales_us@bio-rad.com		Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com		⊢ax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com			
To find a l		ifia alata da at fau th	in much	unt internet und dum aufürd i		, his and satisfied in some (datash sate			
	Datch/lot spec	and datasheet for th	ns prodi	M439309:250523'	search 1001 81:	. มเบ-เลน-สทแมงนเยร.com/datasheets			
				Printed on 23 May 2025					

© 2025 Bio-Rad Laboratories Inc | Legal | Imprint